Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

SEAS leader tags statin-ezetimibe cancer link as most likely a matter of chance

November 1, 2008
By Barabra Boughton
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 11
Volume 17
Issue 11

MUNICH-Final results from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial were released at the 2008 European Society of Cardiology Congress, and the lead researcher urged oncologists to continue treatment for their patients who are also on cholesterol-lowering drugs.

MUNICH-Final results from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial were released at the 2008 European Society of Cardiology Congress, and the lead researcher urged oncologists to continue treatment for their patients who are also on cholesterol-lowering drugs.

In 2001, Terje Pedersen, MD, PhD, and his colleagues began enrolling 1,873 patients with aortic stenosis. The trial was designed to evaluate the risk of cardiovascular events and cardiovascular mortality among patients taking the combination lipid-lowering regimen.

But the group unexpectedly found that the combination therapy-when compared with placebo-seemed to increase cancer risk and mortality. During a median follow- up of 52 months, there was an increase in both the incidence of cancer (101 vs 65 patients; hazard ratio, 1.55) and cancerrelated deaths [37 vs 20 deaths; hazard ratio, 1.78 (see Table)].

“It was a totally unexpected finding-and one that we think is actually quite implausible,” Dr. Pedersen, professor of medicine in the Center for Preventive Medicine at Ulleval University Hospital in Norway, told Oncology News International. “It’s difficult to believe that patients will develop a cancer within a span of four years that will lead to death-merely by taking cholesterol-lowering pills.”

Last month, U.S. Food and Drug Administration announced that it would continue to monitor a possible increased cancer risk in association with the use of simvastin (Zocor) and ezetimibe (Zetia), which are marketed in combination as Vytorin. The agency also said that it was awaiting results from the SEAS trial that would take six months to review (see “Common cholesterol drugs may be linked to escalated cancer risk,” September 2008, page 6).

Dr. Pedersen noted that the cancer-related findings of the SEAS trial are based on small numbers and could be due to chance. He also noted that the diff erences between the treatment and placebo groups did not relate to any particular type of cancer and did not become larger with more prolonged treatment (see Figure).

However, the data have been submitted to an independent academic group for analysis, along with results from two other clinical trials that analyzed cholesterol-lowering drugs, SHARP (Study of Heart and Renal Protection) and IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effi cacy International Trial).

SEAS results have been published online in The New England Journal of Medicine (September 2, 2008). In an accompanying NEJM editorial, Thomas R. Fleming, PhD, noted that interim analysis from IMPROVE-IT and SHARP did indicate an increase in the number of cancer-related deaths associated with active vs control therapy-and a 34% increased risk of cancer-related mortality among those taking simvastatin-ezetimibe.

While Dr. Fleming noted that the interim nature of the data from the IMPROVE-IT and SHARP trials is problematic, he also called for more research to clarify the connection between simvasatin-ezetimibe and cancer, preferably through completed randomized trials.

“Such confirmation is especially important in the case of agents such as ezetimibe, for which there are safety signals of major illness or death and evidence of efficacy that is limited to documented eff ects on a biomarker,” Dr. Fleming said.

Dr. Pedersen said he believed that the cancer- related findings in the SEAS, IMPROVEIT, and SHARP trials can be explained by chance, and that cholesterol-lowering drugs do not pose an increased cancer risk.

“I’m not about to recommend that any of my patients stop taking ezetimibe based on these findings,” Dr. Pedersen said.

He added that oncologists who face concern from their patients about cholesterollowering drugs and cancer risk should not stop treatment but should explain the results from the various trials.

Articles in this issue

Move to abandon anthracyclines in adjuvant breast cancer care is premature
Elaine Jaffe: At the forefront of clinical lymphoma biology
Clinical trials struggle to recruit, retain patients
Global financial woes threaten new UK radiotherapy centers
UK health service urges drug cost cuts
Birth length of at least 50 cm may bump up breast ca risk
Obama, NCCN win endorsements in online poll surveys
Colonoscopy proves cost-effective in young patients
Philips Healthcare extends contract for image-guided oncology
US Oncology teams with RTOG to boost trial enrollment
Court finds Roche infringed on Amgen’s erythropoietin patents
Advanced colon ca: Is sequential treatment preferred?
Infusion confusion: Quick fixes for keeping reimbursement on track
Would a higher dose make a difference?
Cancer film festival salutes international documentaries

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
Related Content

Data from the DREAMM-7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.

Belantamab Mafodotin Combo Has Meaningful Benefits in R/R Multiple Myeloma

Russ Conroy
July 26th 2025
Article

Data from the DREAMM-7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Ariana Pelosci
July 25th 2025
Article

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Tim Cortese
July 25th 2025
Article

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Related Content

Data from the DREAMM-7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.

Belantamab Mafodotin Combo Has Meaningful Benefits in R/R Multiple Myeloma

Russ Conroy
July 26th 2025
Article

Data from the DREAMM-7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Ariana Pelosci
July 25th 2025
Article

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Tim Cortese
July 25th 2025
Article

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.